[go: up one dir, main page]

AR076016A1 - DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF AN ILLNESS ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE - Google Patents

DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF AN ILLNESS ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE

Info

Publication number
AR076016A1
AR076016A1 ARP100101061A ARP100101061A AR076016A1 AR 076016 A1 AR076016 A1 AR 076016A1 AR P100101061 A ARP100101061 A AR P100101061A AR P100101061 A ARP100101061 A AR P100101061A AR 076016 A1 AR076016 A1 AR 076016A1
Authority
AR
Argentina
Prior art keywords
domperidone
alteration
prevention
composition according
treatment
Prior art date
Application number
ARP100101061A
Other languages
Spanish (es)
Inventor
Beguer Josep M Homedes
Elias David Sabate
Ochoa Pablo Gomez
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR076016A1 publication Critical patent/AR076016A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Reivindicacion 1: Composicion que comprende domperidona o una sal farmacéuticamente aceptable de la misma para su uso en el tratamiento o la prevencion en un mamífero de una enfermedad asociada a una alteracion de la respuesta inmunitaria, donde la composicion se prepara para la administracion de una dosis diaria de domperidona de desde 0,2 mg/kg/día hasta 1 mg/kg/día. Reivindicacion 5: Composicion segun cualquier reivindicacion anterior, caracterizada porque se prepara como una forma de dosificacion oral para su administracion una vez al día. Reivindicacion 6: Composicion segun cualquier reivindicacion anterior, caracterizada porque es para su uso en el tratamiento o prevencion en un perro de una enfermedad asociada con una alteracion de la respuesta inmunitaria. Reivindicacion 8: Composicion segun cualquier reivindicacion anterior, caracterizada porque es para su uso en el tratamiento o prevencion de una enfermedad seleccionada del grupo de enfermedades asociadas a una alteracion en la inmunidad celular mediada por linfocitos CD4+Th1. Reivindicacion 9: Composicion segun la reivindicacion 8, caracterizada porque la enfermedad es leishmaniosis. Reivindicacion 15: Composicion segun la reivindicacion 14, caracterizada porque comprende tanto domperidona como un agente leishmanicida tal como antimoniato de N-metilglucamina o miltefosina o bien en una unica forma de dosificacion o bien en formas de dosificacion separadas. Reivindicacion 17: Composicion segun la reivindicacion 16, caracterizada porque comprende tanto domperidona como un agente leishmaniostático tal como alopurinol o bien en una unica forma de dosificacion o bien en formas de dosificacion separadas.Claim 1: Composition comprising domperidone or a pharmaceutically acceptable salt thereof for use in the treatment or prevention in a mammal of a disease associated with an alteration of the immune response, wherein the composition is prepared for administration of a dose. Domperidone daily from 0.2 mg / kg / day to 1 mg / kg / day. Claim 5: Composition according to any previous claim, characterized in that it is prepared as an oral dosage form for administration once a day. Claim 6: Composition according to any preceding claim, characterized in that it is for use in the treatment or prevention in a dog of a disease associated with an alteration of the immune response. Claim 8: Composition according to any preceding claim, characterized in that it is for use in the treatment or prevention of a disease selected from the group of diseases associated with an alteration in cellular immunity mediated by CD4 + Th1 lymphocytes. Claim 9: Composition according to claim 8, characterized in that the disease is leishmaniosis. Claim 15: Composition according to claim 14, characterized in that it comprises both domperidone and a leishmanicidal agent such as N-methylglucamine or miltephosin antimonate or in a single dosage form or in separate dosage forms. Claim 17: Composition according to claim 16, characterized in that it comprises both domperidone and a leishmaniostatic agent such as allopurinol either in a single dosage form or in separate dosage forms.

ARP100101061A 2009-03-31 2010-03-31 DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF AN ILLNESS ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE AR076016A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382040A EP2241317A1 (en) 2009-03-31 2009-03-31 Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response

Publications (1)

Publication Number Publication Date
AR076016A1 true AR076016A1 (en) 2011-05-11

Family

ID=40801995

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101061A AR076016A1 (en) 2009-03-31 2010-03-31 DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF AN ILLNESS ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE

Country Status (9)

Country Link
US (1) US8802691B2 (en)
EP (2) EP2241317A1 (en)
AR (1) AR076016A1 (en)
DK (1) DK2413934T3 (en)
ES (2) ES2397193B1 (en)
HU (1) HUE027348T2 (en)
PL (1) PL2413934T3 (en)
PT (1) PT2413934E (en)
WO (1) WO2010112497A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3949965A1 (en) * 2020-08-07 2022-02-09 Consejo Superior de Investigaciones Cientificas Domperidone for use as antiviral agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372818A (en) * 1993-02-01 1994-12-13 Clemson University Method of treating fescue toxicosis with domperidone
US6224895B1 (en) 1996-12-18 2001-05-01 Clemson University Method for promoting ovulation, parturition, and lactation in mammals
US7887817B2 (en) 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
ES2246142B1 (en) 2004-06-03 2007-03-16 Consejo Sup. Investig. Cientificas NEW IMMUNOMODULATING THERAPEUTIC COMPOSITION.

Also Published As

Publication number Publication date
PL2413934T3 (en) 2016-05-31
EP2413934B1 (en) 2015-10-21
ES2397193B1 (en) 2013-11-26
ES2559762T3 (en) 2016-02-15
US8802691B2 (en) 2014-08-12
HUE027348T2 (en) 2016-10-28
PT2413934E (en) 2016-01-25
EP2413934A1 (en) 2012-02-08
ES2397193A2 (en) 2013-03-05
ES2397193R1 (en) 2013-03-25
WO2010112497A1 (en) 2010-10-07
US20120065167A1 (en) 2012-03-15
EP2241317A1 (en) 2010-10-20
DK2413934T3 (en) 2016-01-25

Similar Documents

Publication Publication Date Title
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
HRP20220902T3 (en) Compositions and uses for treating multiple sclerosis
FI3504187T3 (en) Use of pridopidine for treating functional decline
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
MX2016010213A (en) Novel pharmaceutical formulations.
JP2010222367A5 (en)
AR075735A1 (en) PHARMACEUTICAL COMPOSITIONS OF IMMEDIATE RELEASE THAT INCLUDE OXYCODONE AND NALOXONE. USE
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
JP2015532296A5 (en)
JP2017506624A5 (en)
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
AR090885A1 (en) USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2013516493A5 (en)
TN2015000135A1 (en) Modified release formulations for oprozomib
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2024007642A (en) Use of riluzole oral disintigrating tablets for treating diseases.
BR112015019776A2 (en) dual-use oral tablets in sulfate salt pharmaceutical compositions and tablet use methods
PE20130147A1 (en) PHARMACEUTICAL COMBINATION OF THEOBROMINE AND A NON-OPIOID ANTITUSSIVE AGENT
RU2016137926A (en) GRAPHIPRANT COMPOSITIONS AND WAYS OF THEIR APPLICATION
AR098832A1 (en) USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE
HRP20251123T1 (en) EKOPIPAM FOR THE TREATMENT OF TOURETTE'S SYNDROME
AR076016A1 (en) DOMPERIDONE AT A LOW DAILY DOSE FOR USE IN THE TREATMENT OR PREVENTION OF AN ILLNESS ASSOCIATED WITH AN ALTERATION OF THE IMMUNE RESPONSE

Legal Events

Date Code Title Description
FB Suspension of granting procedure